Lifeboat Foundation

McMaster University researcher Sheila Singh and her team have discovered how glioblastoma, a lethal brain cancer, can evade treatments and kill.

The researchers found the cancer cells that survive the first round of radiotherapy or chemotherapy do so by mutating during the post-treatment minimal residual disease (MRD) or dormant state. The MRD profile of each patient was mapped using single cell sequencing to find a genetic signature that predicted how the cancer would recur in each individual.

Singh said that by mapping the MRD, researchers found that each patient had a different trajectory to their cancer recurring, potentially opening the door to future treatments tailored to each individual with glioblastoma. Singh’s team monitored five patients between 2018 and 2022.

In 2012, Nedergaard also helped to discover a network of thin tubes that collect waste fluid from brain cells, known as the glymphatic system. These tubes may drain into the outgoing cerebrospinal fluid, says Nedergaard.

The waste products of brain cells include proteins called beta-amyloid and tau that are thought to be involved in Alzheimer’s disease when they build up in excessive amounts.

In both mice and people, the SLYM also contains immune cells, so it may allow them to detect signs of infection present in the cerebrospinal fluid, says Nedergaard. “It is loaded with immune cells.”

Many neurodegenerative diseases, including Alzheimer’s.

Alzheimer’s disease is a disease that attacks the brain, causing a decline in mental ability that worsens over time. It is the most common form of dementia and accounts for 60 to 80 percent of dementia cases. There is no current cure for Alzheimer’s disease, but there are medications that can help ease the symptoms.

https://www.ibiology.org/neuroscience/connectome/#part-2

Talk Overview: The human brain is extremely complex with much greater structural and functional diversity than other organs and this complexity is determined both by one’s experiences and one’s genes. In Part 1 of his talk, Lichtman explains how mapping the connections in the brain (the connectome) may lead to a better understanding of brain function. Together with his colleagues, Lichtman has developed tools to label individual cells in the nervous system with different colors producing beautiful and revealing maps of the neuronal connections.
Using transgenic mice with differently colored, fluorescently labeled proteins in each neuron (Brainbow mice), Lichtman and his colleagues were able to follow the formation and destruction of neuromuscular junctions during mouse development. This work is the focus of Part 2.
In Part 3, Lichtman asks whether some day it might be possible to map all of the neural connections in the brain. He describes the technical advances that have allowed him and his colleagues to begin this endeavor as well as the enormous challenges to deciphering the brain connectome.

Continue reading “Jeff Lichtman (Harvard) Part 2: Neuromuscular Connectomics” »

IBM Research hosts a fascinating seminar with Rafael Yuste, a world leader in optical methods for brain research. According to Professor Yuste, lifting neuroscience studies from looking at neurons one at a time to ensembles or functional units is key in our quest to understanding how brains work.

Rafael Yuste is a Professor of Biological Sciences and Neuroscience at Columbia University and Co-director of the Kavli Foundations Institute for Neural Circuitry. He recently helped launch the BRAIN Initiative, a large-scale scientific project to systematically record and manipulate the activity of complete neural circuits.

Continue reading “Rafael Yuste: Can You See a Thought? Neuronal Ensembles as Emergent Units of Cortical Function” »

Summary: A new stem cell therapy approach eliminates established brain tumors and provides long-term immunity, training the immune system to prevent cancer from returning.

Source: Brigham and Women’s Hospital.

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents.

U.S. health regulators gave early approval to a new Alzheimer’s drug from Eisai Co. and Biogen Inc., the most promising to date in a new class of medicines that may help slow cognitive decline caused by the disease.

The Food and Drug Administration granted conditional approval to the drug, called lecanemab, based on an early study finding it reduced levels of a sticky protein called amyloid from the brains of people with early-stage Alzheimer’s. The companies will sell it under the brand name Leqembi.

SmartNews is the most efficient way to get all your news now.

Though the team largely explains the function of SLYM in mice, they do study its presence in the adult human brain as well.

The human brain is tremendously complex, and scientists are yet to unlock its full potential. Now, a discovery has identified a previously unknown component of brain anatomy that doubles up as a protective barrier for our grey matter and a platform from which immune cells can monitor the brain, according to a release.

Maiken Nedergaard, co-director of the Center for Translational Neuromedicine at the University of Rochester and the University of Copenhagen, and Kjeld Møllgård, M.D.

Continue reading “Scientists discover new anatomic structure in the brain that monitors and shields cells” »